

CorNotes

CVI SEMINAR SERIES

The next CVI Research Division Seminar will be held on **Thursday, June 16, 2005** in **Building 120, Rm. 360** of the Stritch School of Medicine. The featured speaker will be:

Paul McDermott, Ph.D.
Professor of Medicine
Gazes Cardiac Research Institute
Medical University of South Carolina
Charleston, SC

The title of Dr. McDermott's lecture is:

"The Role of Translational Mechanisms in Regulating Cardiac Protein Synthesis"

For further information about the CVI Seminar Series, contact Dr. Leanne Cribbs at x72817.

CVI JOURNAL CLUB

June 9.....Dr. Jeske
 June 23.....Dr. Hoppensteadt

For further information, contact Dr. Ken Byron at x72819.

FALK CARDIOVASCULAR RESEARCH FELLOWSHIPS

Applications are being accepted for Falk Cardiovascular Research Fellowships. Support is for full-time, basic or clinical research by qualified applicants training in cardiovascular sciences under the sponsorship of a Loyola faculty member. Fellowship applicants should hold MD, DO, DVM, and/or PhD degrees with less than 5 years of previous postdoctoral research training at time of award activation. (Note revised inclusion criteria). Funds may be used for salary supplementation up to a total of \$35,568 (exclusive of fringe benefits) per fellow. Up to \$5,000 per year may be used for supplies and small

equipment. The total budget should not exceed \$46,060. Funding is available for a period of up to 2 years.

Applications are in the form of either an NIH Individual NRSA or an AHA Postdoctoral Fellowship. If a similar extramural postdoctoral fellowship application was previously reviewed externally, applicants should provide pink sheets, and indicate if or how the Falk fellowship proposal differs from the original submission.

A cover letter should include the proposed budget, including other sources of support for the fellow's stipend. Questions about the program should be directed to Allen M. Samarel, MD, Director of Research, CVI at x72821, or via e-mail at asamare@lumc.edu. Applications should be submitted to:

Ms. Georgia Keleher
Administrative Assistant, CVI
Room 5220, Building 110, LUMC
Deadline for submission is July 1, 2005

CARDIOLOGY - CVI RESEARCH DIVISION BASIC SCIENCE SEMINAR

The Cardiology Division and the CVI Research Division are sponsoring a series of joint seminars by Loyola Faculty. The following seminar is scheduled:

June 3.....Dr. Samarel

The title of Dr. Samarel's talk is:

"Vascular Endothelial Growth Factor and Cardiomyocyte Mechanotransduction"

During the renovation of the Van Kampen Conference Center, seminars will be held at 12:00 pm in the CVI Research Division Conference Room, Rm 5215.

For further information, contact Dr. Samarel at x72821

DR. MORAN RECEIVES DAMEN AWARD

Congratulations to Dr. John F. Moran (B.S. '60; M.D. '64) who is the 2005 recipient of the Damen Award from the Stritch School of Medicine. Dr. Moran will receive this prestigious award from Fr. Michael Garanzini at the Founders' Dinner on Saturday, June 4, 2005 at the Lake Shore Campus. Tickets for the event can be purchased by contacting Rob Smit at 5-6451 or rsmit1@luc.edu.

HEART FAILURE / TRANSPLANT TEAM SEEKS ENROLLMENT FOR THE "UNLOAD" TRIAL

Dr. Alain Heroux of the Section of Heart Failure/Transplant is the Principal Investigator conducting the UNLOAD clinical trial on behalf of CHF Solutions, Inc.

The purpose of this study is to assess a number of safety, efficacy, and financial endpoints comparing ultrafiltration (as performed with the System 100) with IV diuretics (standard medical therapy) over a 3-month period in patients hospitalized for acute decompensated congestive heart failure.

Ultrafiltration removes excess water without causing a significant clinical change in the electrolyte composition of the blood or without causing adverse effects on the kidneys and neurohormonal system. Studies have shown that UF increases urine output, increases responsiveness to standard oral therapies, and decreases readmission rates. Therefore, it is important to determine whether the System 100 can improve the acute management of patients with acute decompensated congestive heart failure and maintain this improvement over a period of time compared to IV diuretics. UF in this patient population may decrease the length of hospital stay and reduce hospital readmissions for heart failure leading to a significant reduction in costs for the treatment of these patients.

Participants must be hospitalized with acute decompensated heart failure with evidence of fluid overload and must present with at least 2 of the following conditions: +2 pitting edema, JVD, pulmonary edema, ascites, and 2-pillow orthopnea. Participants cannot be post-transplant.

For more information or to alert the Heart Failure/Transplant team of potential participants, please contact the project's coordinator, Melissa Hill, at 708.327.2723.

RECENT PUBLICATIONS FROM THE CVI

Ziolo, M.T., Martin, J.L., Bossuyt, J., Bers, D.M., Pogwizd, S.M. Adenoviral gene transfer of mutant phospholamban rescues contractile dysfunction in failing rabbit myocytes with relatively preserved SERCA function. *Circ. Res.*, 96: 815 – 817, 2005.



Preparing People to Lead Extraordinary Lives

**LOYOLA
UNIVERSITY
CHICAGO**

Stritch School of Medicine